NCT05564377 2026-04-16
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
19 trialsNCT06545682 2026-04-16
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05948943 2026-04-14
EPIK-L1
Novartis
Phase 2/3 Recruiting
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT05038735 2026-04-08
EPIK-B5
Novartis
Phase 3 Active not recruiting
NCT05631795 2026-04-07
ALPINIST
Novartis
Phase 4 Completed
NCT04251533 2026-04-03
EPIK-B3
Novartis
Phase 3 Terminated
NCT04208178 2026-04-02
EPIK-B2
Novartis
Phase 3 Active not recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT01872260 2026-04-01
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis
Phase 1/2 Active not recruiting
NCT05230810 2026-03-16
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
Criterium, Inc.
Phase 1/2 Active not recruiting
NCT04729387 2026-03-13
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Novartis
Phase 3 Terminated
NCT05154487 2026-03-03
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT05983159 2026-02-19
TARGET-VM
Murdoch Childrens Research Institute
Phase 2 Recruiting
NCT05101564 2026-02-12
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Stanford University
Phase 2 Completed
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT05646862 2026-02-05
INAVO121
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03138070 2026-01-28
A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting